Engineering HIV-1-Resistant T-Cells from Short-Hairpin RNA-Expressing Hematopoietic Stem/Progenitor Cells in Humanized BLT Mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Down-regulation of the HIV-1 coreceptor CCR5 holds significant potential for long-term protection against HIV-1 in patients. Using the humanized bone marrow/liver/thymus (hu-BLT) mouse model which allows investigation of human hematopoietic stem/progenitor cell (HSPC) transplant and immune system reconstitution as well as HIV-1 infection, we previously demonstrated stable inhibition of CCR5 expression in systemic lymphoid tissues via transplantation of HSPCs genetically modified by lentiviral vector transduction to express short hairpin RNA (shRNA). However, CCR5 down-regulation will not be effective against existing CXCR4-tropic HIV-1 and emergence of resistant viral strains. As such, combination approaches targeting additional steps in the virus lifecycle are required. We screened a panel of previously published shRNAs targeting highly conserved regions and identified a potent shRNA targeting the R-region of the HIV-1 long terminal repeat (LTR). Here, we report that human CD4(+) T-cells derived from transplanted HSPC engineered to co-express shRNAs targeting CCR5 and HIV-1 LTR are resistant to CCR5- and CXCR4- tropic HIV-1-mediated depletion in vivo. Transduction with the combination vector suppressed CXCR4- and CCR5- tropic viral replication in cell lines and peripheral blood mononuclear cells in vitro. No obvious cytotoxicity or interferon response was observed. Transplantation of combination vector-transduced HSPC into hu-BLT mice resulted in efficient engraftment and subsequent stable gene marking and CCR5 down-regulation in human CD4(+) T-cells within peripheral blood and systemic lymphoid tissues, including gut-associated lymphoid tissue, a major site of robust viral replication, for over twelve weeks. CXCR4- and CCR5- tropic HIV-1 infection was effectively inhibited in hu-BLT mouse spleen-derived human CD4(+) T-cells ex vivo. Furthermore, levels of gene-marked CD4(+) T-cells in peripheral blood increased despite systemic infection with either CXCR4- or CCR5- tropic HIV-1 in vivo. These results demonstrate that transplantation of HSPCs engineered with our combination shRNA vector may be a potential therapy against HIV disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G. M., Kohn, D. B., Gregory, P. D., Holmes, M. C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1663 · Cited by 677
A detailed model of reverse transcription and tests of crucial aspects
Gilboa, E., Mitra, S. W., Goff, S., & Baltimore, D. (1979) · Cell · doi:10.1016/0092-8674(79)90357-x · Cited by 612 · cited 1×
“sequences during reverse transcription [20,44].”
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases
Wilen, C. B., Wang, J., Tilton, J. C., Miller, J. C., Kim, K. A., Rebar, E. J., Sherrill-Mix, S. A., Patro, S. C., Secreto, A. J., Jordan, A. P. O., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002020 · Cited by 142 · cited 1×
“receptor-virion interaction has elicited much therapeutic interest [8,11,12].”
BackgroundKlasens, B. I. F., Thiesen, M., Virtanen, A., & Berkhout, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.2.446 · Cited by 80 · cited 2×
“Directing RNAi toward the sh516 target sequence provides several advantages: 1) high conservation across multiple R5- and X4tropic strains may provide broad protection; 2) all transcripts derived from HIV-1 genomes bearing the sh516 target sequence within their LTR R regions are susceptible to RNAi, resulting in effic…”
Background
Cited by
Lundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Wen, J., Wu, D., Qin, M., Liu, C., Wang, L., Xu, D., Vinters, H. V., Liu, Y., Kranz, E., Guan, X., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0434-z · Cited by 108
Self-citationHofer, U., Henley, J. E., Exline, C. M., Mulhern, O., Lopez, E., & Cannon, P. M. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit382 · Cited by 43
“approaches have included a chimeric aptamer-siRNA combination [23], the combination of shRNAs against both CCR5 and HIV [24], HIV-neutralizing antibodies [25, 26], and the triple combinationof a trans-activating response element (TAR)decoy,”
BackgroundDudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Metadata
- Authors
- Ringpis, G.-E. E., Shimizu, S., Arokium, H., Camba-Colón, J., Carroll, M. V., Cortado, R., Xie, Y., Kim, P. Y., Sahakyan, A., Lowe, E. L., Narukawa, M., Kandarian, F. N., Burke, B. P., Symonds, G. P., An, D. S., Chen, I. S. Y., & Kamata, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-31
- Volume
- 7
- Issue
- 12
- Pages
- e53492
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2137180811
- Cited by
- 86
- References
- 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.